Insulin therapy in type 2 diabetes
21 results
1 - 21
SGLT2 inhibitors, GLP1 agonists provide greater benefit for patients with type 2 diabetes- Basal insulin less effective, better tolerated than biphasic and prandial
- Fracture risk based on BMD and FRAX score higher in adults with type 2 diabetes
- Similar long-term morbidity and mortality with human insulin and analogue insulins
- Risk of severe hypoglycemia similar between different insulin formulations
- For post-thrombolysis hyperglycemia: no reduction in symptomatic intracerebral hemorrhage with continuous intravenous insulin therapy
- Little benefit to revascularization over intensive medical treatment in DM with CAD
- NPH insulin: fewer episodes of severe hypoglycemia than analogs (Lantus and Levemir) and less than half the cost
- Intensive glucose therapy during hospitalization for stroke does not improve functional outcomes (SHINE)
- Closed-loop system improves glycemic control but not hypoglycemia for young children with type 1 diabetes mellitus
- Moderately intensive control of T2DM improves clinical outcomes (UKPDS)
- Continuous glucose monitoring adds little benefit, especially in adults
- Type 2 diabetes: metformin first, other treatments second
- J-shaped survival curve for glycemic control in patients with type 2 DM
- Weekly tirzepatide + metformin better than daily insulin degludec + metformin in decreasing A1C, weight, and hypoglycemia (SURPASS-3)
- Glargine and liraglutide are the best second drugs after metformin for achieving tight glycemic control (in a study without SGLT2 inhibitors)
- Intensive control of glucose does not improve T2DM outcomes (VADT)
- Liraglutide probably the best second drug to prevent cardiovascular events in patients with T2DM who take metformin
- Adding dulaglutide only slightly decreases major adverse CV events in patients with T2DM and CVD risk factors (REWIND)